Gene: VTI1A

143187
MMDS3|MVti1|VTI1RP2|Vti1-rp2
vesicle transport through interaction with t-SNAREs 1A
protein-coding
10q25.2
Ensembl:ENSG00000151532 MIM:614316 Vega:OTTHUMG00000019063 UniprotKB:Q96AJ9
NC_000010.11
PubMed|SNP Mapped
1   ANCO-SNPs
CD|ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.364e-1 (AD)  1.489e-2 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs77409651chr10:112642215 (GRCh38.p7)T>Acocaine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
DCTN50.893
TCP11L10.873
ZNF1340.869
FBXO110.865
MTPN0.86
ARFGEF10.859
RNF1110.857
DYM0.855
YIPF50.854
NRIP10.854

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.418
OR4F29-0.394
S100A1-0.379
TPPP2-0.311
APOA1-0.31
PON1-0.308
LFNG-0.302
NXNL1-0.295
CSAG1-0.295
PLIN4-0.291

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0164032,4-dinitrotoluene"2,4-dinitrotoluene affects the expression of VTI1A mRNA"21346803
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VTI1A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VTI1A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of VTI1A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VTI1A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VTI1A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of VTI1A mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of VTI1A mRNA19770486
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of VTI1A mRNA24449571
D001151ArsenicArsenic affects the methylation of VTI1A gene25304211
D001280AtrazineAtrazine results in increased expression of VTI1A mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of VTI1A mRNA20064835|2010694
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of VTI1A mRNA19770486|2171566
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of VTI1A mRNA"26238291
C006780bisphenol Abisphenol A affects the expression of VTI1A mRNA21786754
C006780bisphenol Abisphenol A affects the expression of VTI1A mRNA21786754
C006780bisphenol Abisphenol A results in decreased expression of VTI1A mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of VTI1A gene28505145
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of VTI1A mRNA28628672
D000068579CelecoxibCelecoxib results in increased expression of VTI1A mRNA28201806
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VTI1A mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in decreased expression of VTI1A mRNA26272509
D003042CocaineCocaine affects the expression of VTI1A mRNA20187946
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of VTI1A mRNA28628672
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of VTI1A mRNA17361019|2126653
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of VTI1A mRNA27392435
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of VTI1A mRNA17555576
D005947Glucose[INS protein co-treated with Glucose] results in increased expression of VTI1A mRNA22634610
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of VTI1A mRNA28628672
C051890irinotecanirinotecan analog results in decreased expression of VTI1A mRNA18927307
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of VTI1A mRNA28628672
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of VTI1A mRNA27392435
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of VTI1A mRNA28001369
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of VTI1A mRNA25729387
C023036perfluorooctanoic acidperfluorooctanoic acid results in increased expression of VTI1A protein26879310
C023036perfluorooctanoic acidperfluorooctanoic acid results in decreased expression of VTI1A protein26879310
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VTI1A mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of VTI1A mRNA26272509
D010936Plant ExtractsPlant Extracts results in increased expression of VTI1A mRNA23557933
D012402RotenoneRotenone results in increased expression of VTI1A mRNA19013527
C009277sodium arsenatesodium arsenate results in increased expression of VTI1A mRNA21795629
D012969Sodium FluorideSodium Fluoride results in decreased expression of VTI1A protein28918527
D013605T-2 ToxinT-2 Toxin results in increased expression of VTI1A mRNA26141394
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of VTI1A mRNA21570461
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of VTI1A mRNA25729387
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of VTI1A mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of VTI1A mRNA23179753|2627250
D014635Valproic AcidValproic Acid results in increased expression of VTI1A mRNA28001369
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of VTI1A gene25560391
D014750VincristineVincristine results in decreased expression of VTI1A mRNA23649840

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000149SNARE binding-IBA21873635  
GO:0005484SNAP receptor activity-IBA21873635  
GO:0005484SNAP receptor activity-IDA15215310  
GO:0005515protein binding-IPI24095276  
GO ID GO Term Qualifier Evidence PubMed
GO:0006623protein targeting to vacuole-IBA21873635  
GO:0006888ER to Golgi vesicle-mediated transport-IBA21873635  
GO:0006888ER to Golgi vesicle-mediated transport-ISS-  
GO:0006891intra-Golgi vesicle-mediated transport-IBA21873635  
GO:0006896Golgi to vacuole transport-IBA21873635  
GO:0006914autophagy-IMP24095276  
GO:0042147retrograde transport, endosome to Golgi-IBA21873635  
GO:0042147retrograde transport, endosome to Golgi-IDA15215310  18195106  
GO:0042147retrograde transport, endosome to Golgi-IMP19224922  
GO:0048280vesicle fusion with Golgi apparatus-IBA21873635  
GO:0048280vesicle fusion with Golgi apparatus-ISS-  
GO:0050882voluntary musculoskeletal movement-IMP22958904  
GO:0090161Golgi ribbon formation-IMP23677696  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-TAS-  
GO:0005768endosome-ISS-  
GO:0005776autophagosome-IDA24095276  
GO:0005789endoplasmic reticulum membrane-IBA21873635  
GO:0005794Golgi apparatus-IBA21873635  
GO:0005794Golgi apparatus-IDA19224922  
GO:0005829cytosol-IEA-  
GO:0008021synaptic vesicle-ISS-  
GO:0012507ER to Golgi transport vesicle membrane-IBA21873635  
GO:0016021integral component of membrane-IEA-  
GO:0030136clathrin-coated vesicle-ISS-  
GO:0031201SNARE complex-IBA21873635  
GO:0031201SNARE complex-ISS-  
GO:0031201SNARE complex-TAS15215310  
GO:0031902late endosome membrane-IBA21873635  
GO:0032588trans-Golgi network membrane-TAS-  
GO:0043025neuronal cell body-ISS-  
GO:0043231intracellular membrane-bounded organelle-IDA-  
GO:0044306neuron projection terminus-ISS-  
GO:0048471perinuclear region of cytoplasm-ISS-  
KEGG ID KEGG Term
hsa04130SNARE interactions in vesicular transport
Reactome ID Reactome Term Evidence
R-HSA-199991Membrane TraffickingTAS
R-HSA-5653656Vesicle-mediated transportTAS
R-HSA-6811438Intra-Golgi trafficTAS
R-HSA-6811440Retrograde transport at the Trans-Golgi-NetworkTAS
R-HSA-6811442Intra-Golgi and retrograde Golgi-to-ER trafficTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25744365Single nucleotide polymorphisms in VTI1A gene contribute to the susceptibility of Chinese population to non-small cell lung cancer. (2015 Jul 22)Su WMInt J Biol Markers
27323854Tobacco smoking and methylation of genes related to lung cancer development. (2016 Sep 13)Gao XOncotarget